Abstract:Objective To investigate the efficacy of short-term biological agent infliximab and immunosuppression combined therapy in patients with active ileocolonic Crohn′s diseases (CD)and to evaluate the mucosal healing.Methods From January 2013 to July 2014,forty hospitalized patients with active ileocolonic CD received at least six times scheduled infliximab injection were enrolled.At week 0, second,and sixth,infliximab 5 mg/kg was administered to induce remission.From the second week, immunosuppression was added.After that,infliximab 5 mg/kg was administered every eight weeks for maintenance treatment.The 36th week after treatment was the end point of follow-up.Before treatment and at the end point of follow-up,the levels of C-reactive protein (CRP),hemoglobin (Hb),clinical remission Crohn′s disease activity index (CDAI)< 150 points,mucosal healing simplified endoscopic activity score for Crohn′s disease (SES-CD)was 0 to 2,partial mucosal healing (SES-CD decreased,but>2 ) and deep remission (achieved both clinical remission and mucosal healing)were compared.T test and Wilcoxon rank sum test were performed for comparison before and after treatment.Results At the 36 th week after treatment,the clinical remission rate was 95 .0% (38/40 ),mucosal healing rate,partial mucosal healing rate and deep remission rate were 62.5 % (25/40),35 .0% (14/40)and 62.5 % (25/40), respectively.The mucosal inflammation of only one case (2.5 %)was not improved.After treatment,the CDAI was 99.3 ±29.3,which was lower than that before treatment (301 .3 ±73.1 )and the difference was statistically significant (t = 17.2,P <0.01 ).Median blood CRP level was 0.8 mg/L(0.1 mg/L, 8.1 mg/L),which was lower than that before treatment (26.8 mg/L(16.1 mg/L,61 .0 mg/L)),the difference was statistically significant (Z = - 5 .3,P < 0.01 ).However,the level of Hb ((134.0 ± 16.0)g/L)was higher than that before treatment ((117.0 ±20.0)g/L),the difference was statistically significant (t=-6.3,P <0.01 ).The median SES-CD was 0 (0,5 ),which was lower than that before treatment (14(8,24)),and the difference was statistically significant (Z =-5 .4,P <0.01 ).Conclusion The short-term (36 weeks)infliximab and immunosuppression combined therapy can achieve high mucosal healing rate and deep remission rate in active ileocolonic CD patients.

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing

Mucosal cytokine expression associated with deep endoscopic mucosal healing in ulcerative colitis

Editorial: chronic DILI and HILI—corticosteroid plus glycyrrhizin as standard therapy? Authors' reply

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply

Editorial: Treatments for inflammatory bowel disease across age‐spectrum—Are they the same? Authors' reply

Emerging Strategy Towards Mucosal Healing in Inflammatory Bowel Disease: What the Future Holds?

Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors.

Clinical study of mesalazine alone and in combination with steroids in treatment of ulcerative colitis

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?

Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras—Authors' reply

Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases.

Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?

Mucosal Healing in Ileocolonic Crohn′s Diseases with Short-Term Infliximab and Immunosuppression Combined Therapy

Letter: the Relationship Between Diet, Mood and Mucosal Healing in Coeliac Disease Remains to Be Verified

Recent Advances in the Management of Acute Severe Ulcerative Colitis

Fecal calprotectin and endoscopic scores: The cornerstones in clinical practice for evaluating mucosal healing in inflammatory bowel disease

Using Corticosteroids to Reshape the Gut Microbiome

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply